Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas  by Fujimura, Taku et al.
Regulatory T Cells Stimulate B7-H1 Expression in
Myeloid-Derived Suppressor Cells in ret Melanomas
Taku Fujimura1,2, Sabine Ring1, Viktor Umansky3, Karsten Mahnke1,4 and Alexander H. Enk1,4
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells, and they promote an
immunosuppressive environment in tumor-bearing hosts. To characterize MDSCs in melanoma, we examined the
expression of inhibitory B7 molecules by CD11bþGr1þ cells isolated frommice with transplantable ret tumors. B7
molecules were expressed on CD11bþGr1þ cells, which also expressed CD124 and inducible nitric oxide
synthase, thus verifying their relation to MDSCs. In developing melanomas, CD11bþGr1þ cells express only low
levels of B7-H1. In contrast, B7-H1 is upregulated in large tumors, and functional analysis demonstrates that
CD11bþGr-1þ cells suppress the proliferation of CD4þ T cells through B7-H1. Depletion of regulatory
T cells (Tregs) significantly downregulated the expression of B7-H1, B7-H3, and B7-H4 on MDSCs and reduced
tumor growth, indicating a concerted immunosuppressive activity of Tregs and MDSCs. No differences in the
suppressive function of MDSCs between CD25-depleted and non-depleted mice were recorded. Instead, tumor-
derived MDSCs from Treg-depleted hosts produced less IL-10 and more IFN-g as compared with Treg-harboring
mice. These studies indicate that Tregs in tumors not only suppress effector T cells directly, but also modify the
phenotype of tumor-infiltrating CD11bþ cells to express inhibitory B7-H molecules and to produce IL-10.
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INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) comprise a group
of heterogeneous CD11bþGr1þ cells, which are character-
ized by their suppressive activity exerted during immune
responses (Sica and Bronte, 2007; Gabrilovich and Nagaraj,
2009; Fujimura et al., 2010). Currently, several reports
suggest that MDSCs are key suppressor cells that down-
regulate antitumor immune responses together with regula-
tory T cells (Tregs) in tumor-bearing hosts (Huang et al.,
2006). The results clearly indicate that expansion and
activation of MDSCs are associated with a poor prognosis
in tumor-bearing hosts (Cheng et al., 2008). Tumor-derived
MDSCs can mediate immunosuppression via augmented
expression of inducible nitric oxide synthase (iNOS) or
arginase-1, and increased production of the immunosuppres-
sive cytokine IL-10 (Sinha et al., 2007; Dugast et al., 2008;
Rodriguez et al., 2009). Recently, several surface molecules,
such as CD115 (macrophage colony-stimulating factor
receptor) and CD124 (IL-4Ra), are also described as markers
for subsets of MDSCs (Gallina et al., 2006; Huang et al.,
2006; Youn et al., 2008). For instance, CD11bþCD115þ
cells directly suppress antigen-stimulated splenocytes
through nitric oxide production, whereas CD11bþCD124þ
MDSCs, but not CD11bþCD124 cells, suppress the gen-
eration of alloreactive cytotoxic T lymphocytes through IL-13
and IFN-g in murine colon carcinoma models (Gallina et al.,
2006; Huang et al., 2006). In particular, for murine MDSCs
even more molecules have been described. For example, the
retinoic acid early inducible-1 (RAE-1) gene, which is known
as the mouse natural killer cell–activating receptor NKG2D, is
expressed on CD11bþGr1þF4/80þ MDSCs isolated from
lymphoma-bearing mice (Nausch et al., 2008).
In parallel to MDSCs, another major subpopulation of
suppressive cells, namely CD4þCD25þFoxp3þ Tregs, is
capable of downregulating the function of immune cells
in tumor-bearing hosts by cell-to-cell contact, secretion
of soluble factors, and/or expression of inhibitory surface
molecules (Viguier et al., 2004; Whiteside, 2010). The
majority of naturally occurring Tregs develop in the
thymus; however, tumors are also able to expand Tregs in
the periphery. Accumulation of Tregs in the tumor micro-
environment was shown to correlate with an unfavorable
prognosis for tumor growth and survival (Zou, 2005;
Whiteside, 2010). One molecule that is frequently attributed
to conveying inhibitory actions among cells is the pro-
grammed death ligand 1 (B7-H1). It is a member of the B7
superfamily, and reports suggest that its tissue expression
is important for mediating tolerance (Keir et al., 2007).
In contrast to the stimulatory B7-1/B7-2–CD28 pathway,
the interaction of B7-H1 with its receptor provides signals
& 2012 The Society for Investigative Dermatology www.jidonline.org 1239
ORIGINAL ARTICLE
Received 29 July 2011; revised 12 October 2011; accepted 24 October 2011;
published online 22 December 2011
1Department of Dermatology, Ruprecht-Karls University of Heidelberg,
Heidelberg, Germany; 2Department of Dermatology, Tohoku University
Graduate School of Medicine, Sendai, Japan and 3German Cancer Research
Center, University Hospital Mannheim, Heidelberg, Germany
Correspondence: Taku Fujimura, Department of Dermatology, Tohoku
University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai
980-8574, Japan. E-mail: tfujimura1@mac.com
4These authors equally contributed to this work.
Abbreviations: DC, dendritic cell; iNOS, inducible nitric oxide synthase;
MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell
downregulating the activation and fine-tuning the T-cell
responses. B7-H1 is widely expressed on hematopoietic cells,
such as B cells, dendritic cells (DCs), macrophages, and
T cells, and is further upregulated upon cell activation. In
myeloid cells such as DCs, B7-H1-induced pathways are able
to inhibit DC activation by increased IL-10 production and
decreased expression of maturation markers such as B7-1 and
B7-2 (Kuipers et al., 2006).
B7-H1, together with the more recently identified B7-H3
and B7-H4 molecules, represent a class of immune regula-
tory molecules which primarily execute their functions in
peripheral tissues to attenuate immune responses in target
organs (Kryczek et al., 2007). In this report, we investigate the
expression and the function of B7-H molecules in MDSCs
during melanoma growth and analyze whether Tregs are
involved in shaping the functional differentiation of MDSCs
in melanomas.
RESULTS
B7-H1, B7-H3, B7-H4, CD124, and RAE-1 are upregulated by
CD11bþGr1þ MDSCs in tumors
At first, we examined the expression of regulatory molecules
and markers of MDSCs on CD11bþGr1þ cells in tumors and
spleens. Figure 1a demonstrates that B7-H1, B7-H3, and B7-
H4 are strongly expressed on CD11bþGr1þ cells derived
from tumors. The molecules CD124 and RAE-1, which were
previously reported as markers for MDSCs, were also
upregulated in tumor-infiltrating CD11bþGr1þ cells. In
contrast, splenic CD11bþGr1þ cells from control or
tumor-bearing mice expressed only low amounts of B7-H3,
B7-H4, CD124, and RAE-1. However, only expression of B7-
H1 was detected in splenic CD11bþGr1þ cells in substantial
amounts, but the expression level was significantly reduced
as compared with tumor-infiltrating CD11bþGr1þ cells
(Figure 1a).
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Figure 1. Phenotypic analysis of myeloid-derived suppressor cells during the growth of transplantable ret melanoma. (a) Surface expression of B7-H1,
B7-H3, B7-H4, CD124, RAE-1 on CD11bþGr1þ cells in tumors and spleens was analyzed by flow cytometry. Tumor size was about 7 mm in diameter.
(b) Expression of B7-H1, B7-H3, and B7-H4 on Gr1þCD11bþ cells during the growth of transplantable melanoma. Shown is the mean percentage
(þ SD) of marker-positive cells among CD11bþGr1þ cells obtained in five independent experiments. *Marks a significant (P¼ 0.05) difference.
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Expression of B7-H1 by CD11bþGr1þ MDSCs is significantly
augmented during tumor growth
Next, we investigated the time course of expression of B7-H1,
B7-H3, and B7-H4 by MDSCs during tumor growth of ret
cells. At early time points (day 4–6 after inoculation) when
tumors became visible, the expression levels of B7-H1 on
CD11bþGr1þ cells derived from tumors was equal to that
recorded in splenic CD11bþGr1þ cells. Interestingly, the
expression of B7-H1 was significantly augmented after
tumors reached 7–10 mm in diameter (Figure 1b). In contrast,
the expression of B7-H3 and B7-H4 by tumor-infiltrating
CD11bþGr1þ cells did not change during tumor growth and
remained high throughout tumor development. Therefore,
B7-H1 expression is regulated during late stages of tumor
growth, whereas B7-H3 and B7-H4 are stably expressed even
in early stages of tumor development.
Tumor-residing CD11bþ MDSCs express iNOS
To examine the phenotype of the tumor-residing CD11bþ
cells beyond B7-H1 expression, we performed immunohis-
tochemical staining for iNOS (Figure 2a). The
CD11bþ iNOSþ double-positive cells were present predo-
minantly in the tumor. In contrast, only few CD11bþ iNOSþ
cells were detected in spleens from tumor-bearing hosts and
control mice (Figure 2b). Therefore, we concluded that
CD11bþ /iNOSþ , and thus presumably immunosuppressive
MDSCs (Dugast et al., 2008), accumulate in transplantable
ret melanomas.
Suppressive function of CD11bþ MDSCs depends on B7-H1
molecules
As almost all CD11bþ cells isolated from tumors expressed
Gr-1 (Figure 1) and iNOS (Figure 2), which is suggestive for
MDSCs, we isolated in the following CD11bþ cells from the
tumors to test their capacity to suppress T-cell proliferation
(Figure 3). MDSCs were isolated from late tumors, as only
those tumors contained sufficient cell numbers for cell
isolation, and (for control purpose) CD11bþ cells were
isolated from spleens. The cells were subsequently cocul-
tured with syngeneic CD4þ T cells and allogeneic bone
marrow–derived DCs as stimulators. In these assays, CD11bþ
cells derived from tumors significantly suppressed the
proliferation of the T cells in a dose-dependent manner at
1:10 and 1:5 ratios of CD11bþ :CD4þ . In contrast, CD11bþ
cells from spleens did not suppress the proliferation of CD4þ
T cells.
As tumor-derived CD11bþ MDSCs significantly upregu-
late expression of the regulatory molecule B7-H1 (Figure 1),
we next tested the contribution of B7-H1 expression by
MDSCs to this suppressive effect. To this end, cocultures of
MDSCs, CD4þ T cells, and allogeneic bone marrow–derived
DCs were set up and B7-H1 molecules were blocked by
specific antibodies (Abs). Figure 3b shows that the suppres-
sive function of CD11bþ cells derived from tumors is
abrogated after blocking B7-H1 molecules on CD11bþ cells
by Abs. Thus, B7-H1 expression is involved in mediating the
suppressive action of MDSCs at least in part. However, we
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Figure 2. Peritumoral infiltration of ret melanoma by CD11bþ iNOSþ myeloid-derived suppressor cells. Established transplantable ret tumors were
surgically removed at days 6–9 after inoculation. (a) Cryosections were examined by CD11b and inducible nitric oxide synthase (iNOS) antibody staining.
The typical iNOS expression in CD11bþ cells in tumors and spleens is shown (red: CD11b, green: iNOS, yellow: merge, bar¼50 mm). (b) Several sections
were analyzed and cells were counted per visible field. A summary of three experiments (þ SD) is given and *marks a significant (P¼ 0.05) difference.
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were not able to completely restore the proliferation of
the CD4þ responder T cells at the high CD11bþ :CD4þ ratio
of 1:5.
Depletion of CD4þCD25þFoxp3þ Tregs suppresses the ret
tumor growth in vivo and downregulates expression of B7-H
molecules in tumor-derived MDSCs
To investigate the effect of Tregs on differentiation of MDSCs,
we depleted Tregs by intraperitoneal injection of CD25-
specific Abs (clone PC61) 4 days before and 6 days after
tumor inoculation, recorded the tumor growth, and analyzed
the phenotype of the tumor-residing MDSCs. Figure 4a shows
that administration of PC61 substantially suppressed the
growth of ret tumors. On killing the mice 12 days after tumor
inoculation, we examined the expression of B7-H1, B7-H3,
and B7-H4 on MDSCs. We found that the expression of
these molecules was significantly downregulated in tumor-
derived CD11bþ cells after depletion of Tregs (P¼0.0178,
Po0.0001, P¼ 0.0075; Figure 4b).
To further investigate the effect of depletion of Tregs on the
expression of iNOS in tumor-residing and splenic MDSCs, we
isolated these cells from respective tissues and prepared
cytospins. Staining of the cells for iNOS and CD11b with
appropriately labeled Abs revealed that tumor-infiltrating
MDSCs from depleted, as well as from non-depleted, mice
express substantial amounts of iNOS (Figure 4c). Moreover,
when counting positive cells from three representative fields
of different cell preparations, we could not detect significant
effects of depletion of Tregs on the frequency of iNOSþ
MDSCs in the tumor tissue, indicating thereby that iNOS
expression is not influenced by the presence of Tregs.
Depletion of Tregs downregulates IL-10 production and
augments production of IFN-c by MDSCs in vitro
As we concluded that the suppressive function of tumor-
derived CD11bþ cells (at least in part) depends on the
expression of B7-H1, we further investigated the effect of
depletion of Tregs on B7-H1 expression by CD11bþ MDSCs.
We isolated CD11bþ cells from the different groups of
mice by magnetic activated cell sorting (MACS) sorting and
performed suppression assays. Unexpectedly, there was no
significant difference in the direct suppressive function of
tumor-derived CD11bþ cells from each group (Figure 5a).
However, we further evaluated the production of cytokines,
which were reported to be produced by MDSCs. To this end,
CD11bþ cells from each group were isolated and stimulated
by lipopolysaccharide (LPS), and subsequently the cytokines in
the tissue culture supernatants were quantified by ELISA.
Substantial amounts of IL-10 were detected in the tissue culture
supernatant of tumor-derived MDSCs. Interestingly, the pro-
duction of IL-10 was significantly downregulated in the
supernatant of tumor-derived MDSCs from Treg-depleted mice
(Figure 5b). In contrast, the production of IFN-gwas augmented
after the Treg depletion (Figure 5c). IL-13, which was reported
to be produced by MDSCs (Gallina et al., 2006; Sica and
Bronte, 2007), was not detected in any group (data not shown).
Thus, these data indicate that the depletion of Tregs down-
regulates production of suppressive IL-10 and upregulates
production of immunostimulatory IFN-g by MDSCs, supporting
the notion that the Treg depletion promotes the MDSC con-
version into a less immunosuppressive phenotype.
DISCUSSION
MDSCs can be found in tumor-bearing mice and in patients
with cancer. In mice, several molecules such as CD124 and
CD115 have been described as MDSC-specific markers
(Gallina et al., 2006; Huang et al., 2006; Rodriguez et al.,
2009). However, their expression varies, suggesting a
phenotypic heterogeneity of MDSCs and underlining the
importance of assessing the suppressive function of MDSCs.
We found that tumor-derived, CD11bþ MDSCs upregu-
late the expression of the immunosuppressive molecule
B7-H1. B7-H1 is known to suppress the T-cell proliferation
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Figure 3. Myeloid-derived suppressor cells from transplantable ret
melanoma suppress the proliferation of syngeneic CD4þ T cells stimulated
by allogeneic bone marrow–derived DCs (BMDCs) in vitro. (a) Indicated
amounts of CD11bþ cells from ret melanoma or spleens were cocultured
with syngeneic CD4þ cells and allogeneic BMDCs for 72 hours. Proliferation
of T cells was determined by 3H-thymidine incorporation and expressed as
counts per minute (c.p.m.). One representative experiment out of four is
shown. (b) B7-H1-specific antibodies (10 mg ml1) and respective isotype
control antibodies were added to cultures as described in a. The graph
presents the relative mean proliferation (þ SD) of three independent
experiments in relation to the positive control (proliferation of CD4þ
T cellsþAPC is set to 100%). *Marks a significant difference (P¼0.05)
between samples. APC, antigen-presenting cell.
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directly (Bedke et al., 2010), and is reported to correlate with
a bad prognosis for malignant melanoma patients (Hino et al.,
2010). Further evidence suggests that the tumor environment
is instrumental for B7-H1 expression. For instance, factors
released by tumors can stimulate B7-H1 expression in
myeloid DCs, which are present in ovarian tumors and the
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respective draining lymph nodes (Curiel et al., 2004).
Therefore, the tumor stroma profoundly decreases the
capacity of DCs to activate antitumor T-cell responses (Curiel
et al., 2003; Zou, 2005). Moreover, tumors can also induce
expression of B7-H1 in T cells directly, which in turn leads to
reduced IL-12 production by myeloid DCs, resulting in
impaired priming of tumor-specific T cells. In line with these
reports, our results demonstrate that in addition to DCs and
T cells, also MDSCs exhibit increased surface expression
of B7-H1 molecules in melanoma-bearing mice. Thus, at
late stages of tumor growth, the ret transplantable mela-
noma maintains a suppressive tissue environment by driving
increased expression of B7-H1 in CD11bþ MDSCs.
A second well-defined population of immunosuppressive
cells, which has a role in impeding antitumor immunity,
comprises Tregs. In several tumor models, it has been shown
that depletion of Tregs alone is sufficient to reestablish tumor
immunity. Our results corroborate these data by demonstrat-
ing increased activation of CD4þ and CD8 Tþ cells (data not
shown) and the suppression of tumor growth after Treg
depletion. Furthermore, we show a reduced expression of the
immunosuppressive molecules B7-H1, B7-H3, and B7-H4 on
tumor-derived CD11bþ MDSCs, and we recorded dimin-
ished amounts of IL-10 and elevated levels of IFN-g produced
by tumor-derived MDSCs after depletion of Tregs. Thus, these
date indicate that Tregs may exert immunomodulatory effects
on MDSCs. Until now, only the inverse interactions, i.e.,
effects of MDSCs on Tregs have been observed. For instance,
MDSCs were shown to induce Tregs de novo in the tumor
microenvironment (Huang et al., 2006; Serafini et al., 2008;
Gabrilovich and Nagaraj, 2009; Fujimura et al., 2010) or to
drive adoptively transferred, antigen-specific CD25CD4þ
T cells into immunosuppressive Tregs (Huang et al., 2006).
In the ret spontaneous tumor model (Kimpfler et al., 2009),
the effect of Tregs on tumor growth was rather small, as
depletion of Tregs alone did not alter the tumor size
significantly. However, in this model, melanomas develop
much slower as compared with the transplantation model,
which may provide other Treg-independent mechanisms to
the tumor to escape immune surveillance. Therefore, Treg
depletion may be ineffective to boost anti-melanoma
immunity in the ret spontaneous tumor model.
Among the possible mechanisms by which MDSCs
suppress immune reactions, the secretion of IL-10, and the
release of nitrogen and oxygen reactive species are reported
as factors inhibiting T-cell proliferation (Bronte et al., 2003;
Sica and Bronte, 2007; Fujimura et al., 2010). However,
when analyzing these soluble mediators, we observed, in
particular, a downregulation of the IL-10 production by
MDSCs after depletion of Tregs. This may readily impede the
suppressive function of MDSCs, as IL-10 has been reported to
diminish the production of type 1 cytokines (IFN-g, IL-12 and
so on) in macrophages and to inhibit the maturation of DCs
(Ostrand-Rosenberg and Sinha, 2009; Schmid and Varner,
2010). Indeed, in parallel to the decreased production of
IL-10 by MDSCs from CD4þCD25þFoxp3þ Treg-depleted
hosts, we frequently observed a substantial upregulation of
expression of major histocompatibility complex class II
molecules on other immune cells such as DCs and B cells
(data not shown). This may be a result of reduced IL-10 levels
in respective hosts and could promote an induction of
activated CD4þ and CD8þ cells.
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IL-10 is also known to increase the expression of co-
inhibitory molecules such as B7-H1 and B7-H4 within the
tumor microenvironment (Zou, 2005; Kryczek et al., 2007;
Yi and Chen, 2009). For instance, in patients with ovarian
cancer, Tregs enable macrophages to spontaneously produce
IL-10, which resulted in the augmentation of B7-H4 expression
on tumor-associated macrophages (Kryczek et al., 2007).
Similarly, our results show that the depletion of Treg reduced
expression of B7-H1, B7-H3, and B7-H4 on MDSCs, thereby
suggesting that the reduction of IL-10 produced by CD11bþ
cells may account for this effect. Although we could not show
that the reduced expression of the B7-H3 and B7-H4 molecules
by MDSCs resulted in a directly decreased suppressive activity
in vitro, the in vivo effects of this reduced expression may be
beneficial for the induction of antitumor immunity.
B7-H3 and B7-H4 belong to a new class of immune
regulatory molecules, which primarily execute their functions in
peripheral tissue to fine-tune immune responses in target organs
(Yi and Chen, 2009). B7-H3 has been identified on T cells, NK
cells, DCs, and macrophages, and at least in DCs its expression
is stimulated by Tregs (Mahnke et al., 2007). Thus, our results
corroborate these in vitro studies by showing reduced B7-H3
levels on MDSCs after Treg depletion in vivo as well.
Taken together, our data suggest the existence of a cross
talk between Tregs and MDSCs. As Treg depletion is
increasingly used in clinical settings, it is critically important
to test interactions between Tregs and MDSCs in various
tumor entities. Therefore, a combinatorial therapy targeting
both Tregs and MDSCs may be beneficial for boosting the
immune system in cancer patients.
MATERIALS AND METHODS
Animals and melanoma cell line
C57BL/6 mice and BALB/c mice (5 to 8 weeks old) were purchased
from Charles River (Sulzfeld, Germany) and housed in the animal
facility at the University of Heidelberg. All experiments were
approved by the state of Baden-Weurttemberg and performed in
accordance with the governmental guidelines. All tissue culture
media and buffers were purchased from PAA Laboratories (Coelbe,
Germany), except indicated reagents. All plastic were purchased
from Becton Dickinson (Heidelberg, Germany). LPS was purchased
from Sigma (Deisenhofen, Germany). The murine melanoma cell
line, ret, was cultured in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum.
Reagents
The following Abs were used in this study: anti-CD4 (L3T4) APC,
anti-CD4 FITC, anti-Foxp3 FITC staining kit, anti-CD11b (M1/70)
APC, anti-B7H1 (MIH5) PE, anti-B7H3 (M3.2D7) PE, anti-B7H4
(188) PE, blocking anti-B7H1, and the respective isotype controls
were purchased from eBioscience (Frankfurt, Germany). PE-con-
jugated anti-CD124 (mIL4R-M1), PE-conjugated anti-Gr1 (RB6-8C5)
Abs, and purified anti-CD11b (M1/70) were purchased from BD
Bioscience (Heidelberg, Germany). The PE-conjugated anti-RAE1 Ab
was obtained from R&D Systems (Bad Nauheim, Germany), and the
anti-iNOS Ab from Abcam (Cambridge, UK). Collagenase type 4 was
purchased from Cell systems (Troisdorf, Germany). DNase1 and LPS
were from obtained from Sigma.
Tumor inoculation and PC61 treatment
A volume of 100ml of 5 106 cells per ml of ret melanoma cells
were subcutaneously injected into female C57BL/6 mice as
described previously (Johnson et al., 2008). The size of established
tumors was measured with a caliper (Mitsutoyo, Utsunomiya, Japan)
and the volume was calculated using the following formula: p/
6 lengthwidth2 (Fujimura et al., 2006). In some experiments,
300mg per mouse PC61 4 days before and 6 days after tumor
inoculation was injected intraperitoneally.
Flow cytometry
For FACS analysis, 1 105 cells were resuspended in phosphate-
buffered saline/1% fetal calf serum and incubated with a combina-
tion of Abs for 30 minutes at 4 1C. After washing, cells were kept in
phosphate-buffered saline/1% FSC. Intracellular staining of Foxp3
was performed using the Foxp3 staining kit according to the
manufacturer’s instructions. In all experiments, cells were analyzed
using a FACS-Canto flow cytometer and appropriate BD FACSDiva
5.0 software (Heidelberg, Germany).
Immunohistochemical staining
Ret tumor-bearing C57BL/6 mice were killed at days 6–9 and tumors
and spleens were removed. Each organ was frozen in optimal cutting
temperature-embedding medium and 6mm sections were fixed with
cold acetone for 10 minutes and blocked with IF buffer (RPMI, 0.5%
saponin, 0.5 mM HEPES, 0.5 mM glycin, 10% goat serum). Thereafter,
each section was first incubated with anti-iNOS Ab at 4 1C overnight,
followed by incubation with FITC-conjugated secondary reagents
(Goat anti-Rabbit; Abcam) for 1 hour at room temperature. There-
after, anti-CD11b mAbs were added for 1 hour and visualized using
TRITC-conjugated Goat anti-Rat Ab (Dianova, Hamburg, Germany).
The slides were mounted in PermaFluor (Lipshaw Immunon,
Pittsburgh, PA) and examined using a Leica DM5500 microscope
equipped with a Spot digital camera.
Purification of CD11bþ cells and CD4þ T cells
CD11bþ cells were isolated from tumor and spleen using MACS
beads (Miltenyi, Bergisch-Gladbach, Germany) according to the
manufacturer’s protocol. Briefly, tumors or spleens were incubated
with collagenase 4 and DNase I for 20 minutes at 37 1C, followed by
mechanical disruption. After single-cell suspensions were obtained,
dead cells were first depleted by using a dead cell removal kit from
Miltenyi according to the manufacturer’s protocol. Thereafter,
aliquots of 107 cells were incubated for 15 minutes with 10ml anti-
CD11b beads (clone M1/70.15.11.5) in 100ml MACS buffer
(phosphate-buffered saline, 0.5 mmol EDTA, 0.5% BSA), washed
two times with MACS buffer, and subjected to two consecutive
rounds of separation via magnetic MS columns (Miltenyi). This
procedure yielded predominantly CD11bþ cells with purity 485%
as assessed by FACS analysis. To obtain T cells as responders for
suppression assays, we isolated CD4þ T cells from lymph nodes and
spleen of untreated C57BL/6 mice by anti-CD4 beads (L3T4,
Miltenyi). The purity of CD4 was 495%.
Generation of murine bone marrow–derived DCs
Murine bone marrow–derived dendritic cells were prepared according
to standard methods (Mahnke et al., 2000). Briefly, bone marrow cells
from naive BALB/c mice were cultured in RPMI 5% fetal calf serum,
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supplemented with granulocyte–macrophage colony-stimulating factor
for 6 days with refeeding. Thereafter, non-adherent cells were harvested
and transferred to six-well dishes and stimulated with LPS (1mg ml1).
T-cell proliferation assays
Bone marrow–derived DCs (5 103 cells per well) were dispensed in
96-well round-bottom plates. Thereafter, MACS bead-isolated
responder CD4þ T cells from spleens and lymph nodes (1 105
cells per well) and graded doses of CD11bþ cells were added.
Plates were incubated at 37 1C for 4 days. The cultures were pulsed
with [3H] Thymidine (Hartmann Analytic, Braunschweg, Germany;
20 mCi per well) 16 hours before harvesting. Incorporated radio-
activity was determined using a beta-plate (Wallac, Turku, Finn-
land). In Ab-blocking experiments, 10 mg ml1 of the respective Abs
was added to the cultures. Unlabeled B7-H1 Abs MIH1 and respec-
tive controls were obtained from eBioscience.
Cytokine ELISA
CD11bþ cells from tumor and spleen of each group were cultured with
or without LPS (1mgml1) in 96-well flat-bottom plates. After 24hours of
culture, supernatants were collected. Secretion of IL-10 (BD Bioscience),
IFN-g (BD Bioscience), and IL-13 (eBioscience) was determined by
ELISA according to the manufacturer’s instructions. Briefly, cytokines
from culture supernatants were immobilized onto 96-well plates and
detected by the respective biotinylated mAb and streptavidin-HRP
conjugate. Enzyme activity was quantified by using tetramethylbenzi-
dine as an indicator for cytokine concentration in the supernatants.
Statistical analysis
For a single comparison of two groups, the unpaired Student’s t-test
was used.
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